Prevail Therapeutics
Company type: Therapeutics
Main focus: Adeno-associated virus (AAV)-based therapies for neurodegenerative conditions
Company stage: Pre-clinical
Diseases: Parkinson’s disease, frontotemporal dementia, Alzheimer’s disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative disorders
Genome-editing tool:
Funding stage: Series B (now a fully owned subsidiary of Eli Lilly)
Location: New York, NY, USA
Website: https://www.prevailtherapeutics.com
Pipeline: https://www.prevailtherapeutics.com/programs/#our-pipeline
Partners: Regenxbio, Scribe Therapeutics
Prevail Therapeutics, a fully owned subsidiary of Eli Lilly, is leveraging adeno-associated virus serotype 9 (AAV9) to deliver gene therapeutics to address devastating neurogenerative disorders including Parkinson’s disease, frontotemporal dementia, Alzheimer’s disease, and Amyotrophic lateral sclerosis (ALS).